4 research outputs found

    Consensus statement on the diagnosis, management, and treatment of angioedema mediated by Bradykinin. Part. II: treatment, follow-up, and special situations

    Full text link
    Background: There are no previous Spanish guidelines or consensus statements on bradykinin-induced angioedema. Aim: To draft a consensus statement on the management and treatment of angioedema mediated by bradykinin in light of currently available scientifi c evidence and the experience of experts. This statement will serve as a guideline to health professionals. Methods: The consensus was led by the Spanish Study Group on Bradykinin-Induced Angioedema, a working group of the Spanish Society of Allergology and Clinical Immunology. A review was conducted of scientifi c papers on different types of bradykinin-induced angioedema (hereditary and acquired angioedema due to C1 inhibitor defi ciency, hereditary angioedema related to estrogens, angioedema induced by angiotensin-converting enzyme inhibitors). Several discussion meetings were held to reach the consensus. Results: Treatment approaches are discussed, and the consensus reached is described. Specifi c situations are addressed, namely, pregnancy, contraception, travelling, blood donation, and organ transplantation. Conclusions: A review of and consensus on treatment of bradykinin-induced angioedema is presentedIntroducci贸n: No existen gu铆as previas espa帽olas sobre el manejo del angioedema mediado por bradicinina. Objetivos: Alcanzar un consenso sobre el manejo y tratamiento del angioedema mediado por bradicinina a la luz de la evidencia cient铆fi ca disponible y la experiencia de los expertos, que sirva como gu铆a para los profesionales de la salud. M茅todos: SGBA/GEAB, un grupo de trabajo de la SEAIC dirigi贸 el consenso. Se realiz贸 una revisi贸n de los documentos cient铆fi cos publicados sobre los diferentes tipos de angioedema mediado por bradicinina [angioedema hereditario o adquirido por defi ciencia de inhibidor de la C1 esterasa, angioedema hereditario relacionado con estr贸genos (AEH tipo III, AEH-FXII), angioedema inducido por IECA (inhibidores del enzima convertidor de angiotensina]. Hubo varias reuniones del SGBA/GEAB para alcanzar el consenso. Resultados: Se revisan y discuten los diferentes tratamientos disponibles y se describe el consenso alcanzado. Se abordan situaciones espec铆fi cas (embarazo, anticoncepci贸n, viajes, hemodonaci贸n, trasplante de 贸rganos). Conclusiones: Se presenta una revisi贸n del tratamiento del angioedema mediado por bradicinina y un consenso sobre su tratamiento en Espa帽aDr. Teresa Caballero is a researcher with the Hospital La Paz Health Research Institute (IdiPaz) program for promoting research activities (2009

    Consensus statement on the diagnosis, management, and treatment of Angiodema mediated by Bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis

    Full text link
    Background: There are no Spanish guidelines or consensus statement on bradykinin-induced angioedema. Aim: To review the pathophysiology, genetics, and clinical symptoms of the different types of bradykinin-induced angioedema and to draft a consensus statement in light of currently available scientifi c evidence and the experience of experts. This statement will serve as a guideline to health professionals. Methods: The consensus was led by the Spanish Study Group on Bradykinin-Induced Angioedema (SGBA), a working group of the Spanish Society of Allergology and Clinical Immunology. A review was conducted of scientifi c papers on different types of bradykinin-induced angioedema (hereditary and acquired angioedema due to C1 inhibitor defi ciency, hereditary angioedema related to estrogens, angioedema induced by angiotensin-converting enzyme inhibitors). Several discussion meetings of the SGBA were held in Madrid to reach the consensus. Results: The pathophysiology, genetics, and clinical symptoms of the different types of angioedema are reviewed. Diagnostic approaches are discussed and the consensus reached is described. Conclusions: A review of bradykinin-induced angioedema and a consensus on diagnosis are presentedIntroducci贸n: No existen gu铆as previas espa帽olas sobre el manejo del angioedema mediado por bradicinina. Objetivos: Revisar la fi siopatolog铆a, gen茅tica y cl铆nica y alcanzar un consenso sobre el diagn贸stico de los diferentes tipos de angioedema mediado por bradicinina a la luz de la evidencia cient铆fi ca disponible y la experiencia de los expertos, que sirva como gu铆a para profesionales de la salud. M茅todos: SGBA/GEAB, un grupo de trabajo de la SEAIC dirigi贸 el consenso. Se realiz贸 una revisi贸n de los documentos cient铆fi cos publicados sobre los diferentes tipos de angioedema mediado por bradicinina [angioedema hereditario o adquirido por defi ciencia de inhibidor de la C1 esterasa, angioedema hereditario relacionado con estr贸genos (AEH tipo III, AEH-FXII), angioedema inducido por IECA (inhibidores del enzima convertidor de angiotensina]. Hubo varias reuniones del SGBA/GEAB para alcanzar el consenso. Resultados: Se revisan la fi siopatolog铆a, gen茅tica y cl铆nica de los diferentes tipos de angioedema por bradicinina. Por otro lado, se discuten los procedimientos diagn贸sticos y se describe el consenso alcanzado sobre el diagn贸stico. Conclusiones: Se presenta una revisi贸n del angioedema mediado por bradicinina y un consenso sobre el diagn贸stico del angioedema mediado por bradicina.Dr. Teresa Caballero is a researcher with the Hospital La Paz Health Research Institute (IdiPaz) program for promoting research activities (2009). Publication of this manuscript is sponsored by the Spanish Society of Allergy and Clinical Immunology (SEAIC) and IdiPa
    corecore